The United States Colorectal Cancer Diagnostics Market is witnessing substantial growth, driven by the rising prevalence of colorectal cancer, increasing awareness of early disease detection, and expanding nationwide screening programs. The growing adoption of advanced diagnostic technologies, including molecular diagnostics, biomarker testing, next-generation sequencing, and non-invasive stool-based screening tests, is enhancing the accuracy and accessibility of colorectal cancer diagnosis across the United States.

Continuous investments in research and the growing burden of colorectal cancer are creating significant Colorectal Cancer Diagnostics Market Opportunities for manufacturers and healthcare organizations worldwide. Healthcare providers are increasingly integrating artificial intelligence, molecular testing, and advanced imaging technologies to improve diagnostic accuracy. According to The Insight Partners, the industry is projected to grow from US$ 10.37 billion in 2022 to US$ 17.0 billion by 2028, registering a CAGR of 8.7% during 2023 to 2028.

Download Sample PDF @ https://www.theinsightpartners.com/sample/TIPRE00013454

Growing Demand for Early Detection and Advanced Screening Technologies

The increasing prevalence of colorectal cancer remains one of the primary factors supporting industry expansion. Governments, healthcare organizations, and cancer awareness programs are encouraging routine screening among high-risk populations to improve survival rates through early diagnosis.

Technological advancements have significantly transformed diagnostic capabilities. AI-assisted colonoscopy systems, advanced imaging platforms, and molecular diagnostic technologies enable physicians to detect suspicious lesions with greater precision while reducing missed diagnoses. The commercialization of intelligent gastrointestinal endoscopy platforms and AI-powered computer-assisted detection systems has enhanced clinical confidence and improved patient outcomes.

Growing acceptance of minimally invasive diagnostic approaches and personalized screening strategies is expected to further accelerate adoption across hospitals and diagnostic centers.

Product Innovation Creates Significant Growth Opportunities

Continuous product development remains one of the strongest growth drivers across the industry. Companies are introducing innovative imaging systems, blood-based diagnostic tests, and AI-enabled software solutions to improve screening efficiency.

Recent technological developments include AI-assisted colonoscopy modules capable of identifying difficult-to-detect polyps in real time, helping physicians improve detection rates during routine procedures. Similarly, advanced endoscopy platforms equipped with computer-aided detection applications support faster and more reliable diagnosis.

Blood-based biomarker technologies are also emerging as promising alternatives for patients seeking non-invasive screening options. Licensing agreements, strategic collaborations, and acquisitions continue to accelerate innovation while expanding access to next-generation diagnostic solutions worldwide.

These innovations create attractive opportunities for manufacturers seeking to differentiate their product portfolios while addressing the growing demand for accurate and patient-friendly diagnostics.

Imaging Tests Continue to Lead Diagnostic Adoption

Based on modality, imaging tests accounted for the largest share in 2022, representing approximately 94.5% of the overall industry. Colonoscopy continues to serve as the gold standard for colorectal cancer diagnosis because of its ability to detect and remove precancerous polyps during the same procedure.

Among imaging technologies, CT colonography is expected to register the fastest growth during the forecast period. The technique offers several advantages, including:

• Rapid examination procedures
• Visualization of the entire colon
• No requirement for sedation
• Improved preoperative tumor assessment
• Enhanced treatment response monitoring

Stool-based diagnostic methods also continue gaining acceptance due to their convenience and affordability. The Fecal Immunochemical Test (FIT) represented the largest share among stool-based testing modalities in 2022, supported by increasing participation in national screening programs.

Hospitals and Regional Expansion Support Industry Growth

Hospitals remain the leading end users due to their advanced infrastructure, experienced specialists, and increasing adoption of technologically advanced diagnostic equipment. The hospital segment is also expected to register the fastest growth through 2028 as healthcare providers continue expanding cancer screening services.

From a regional perspective, North America accounted for 38.4% of the global share in 2022, supported by established screening guidelines, high healthcare expenditure, and rapid adoption of AI-enabled diagnostic technologies.

Meanwhile, Asia Pacific is anticipated to experience the highest growth rate, with a projected CAGR of 9.4% during the forecast period. Rising healthcare investments, improving diagnostic infrastructure, increasing awareness programs, and expanding patient populations are contributing to strong regional demand.

Strategic partnerships, acquisitions, and geographic expansion initiatives further strengthen competitive positioning while increasing access to innovative diagnostic technologies across emerging healthcare markets.

Key Players

Leading companies operating in the colorectal cancer diagnostics industry include:

• Medtronic Plc
• F. Hoffmann-La Roche Ltd
• Illumina Inc
• Quest Diagnostics Inc
• Siemens Healthineers AG
• Eiken Chemical Co., Ltd.
• Bruker Corp
• Epigenomics AG
• Novigenix SA
• Clinical Genomics Technologies Pty Ltd
• EDP Biotech Corp

These organizations continue investing in product innovation, biomarker research, artificial intelligence integration, strategic collaborations, and acquisitions to strengthen their competitive position and expand their global presence.

Future Outlook

The outlook for colorectal cancer diagnostics remains highly positive as healthcare systems increasingly emphasize preventive screening and early intervention. Artificial intelligence, molecular diagnostics, blood-based biomarker testing, and advanced imaging technologies are expected to reshape diagnostic workflows over the coming years.

Related Report:

1) Antibody Drug Conjugates Market Analysis, Size, and Share by 2031

2) Pharmaceutical Excipients Market Growth, Trends & Demand by 2034

3) Enteral Nutrition Market Strategies, Top Players, Growth Opportunities

About Us -

The Insight Partners provides comprehensive syndicated and tailored market research services in the healthcare, technology, and industrial domains. Renowned for delivering strategic intelligence and practical insights, the firm empowers businesses to remain competitive in ever-evolving global markets.

Contact Us:
Ankit Mathur | The Insight Partners
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876

Also Available in : Korean German Japanese French Chinese Italian Spanish